vendor · ships us
Limitless Life Nootropics
Cleanest COAs we've tested, fast US shipping, premium pricing.
91/100
VIAL15
15% off first order
copy
2d ship · last test 2026-04-15T00:00:00.000ZRead audit →
affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
Tirzepatide
MounjaroZepbound
Dual GLP-1 / GIP receptor agonist. FDA-approved as Mounjaro (T2D) and Zepbound (obesity).
§ 01
Research notes
Mechanism
Tirzepatide hits two incretin receptors: GLP-1 and GIP. The dual agonism produces a larger weight-loss and glycemic effect than GLP-1 monotherapy at comparable doses. Marketed as Mounjaro for type 2 diabetes and Zepbound for obesity by Eli Lilly.
Research dosing
Standard escalation schedule starts at 2.5 mg weekly, increasing every four weeks through 5, 7.5, 10, 12.5, and 15 mg. The Surmount trials used this schedule with optimal weight-loss outcomes at the 10–15 mg range.
Vendor coverage
Tirzepatide is the most-stocked compound across the audited vendor pool — every major research vendor lists it, which makes it the natural starting point for cross-vendor purity comparisons. Cross-lab agreement on tirzepatide tends to be tight (<1 percentage point) at the top vendors and looser (2–4 points) at the bottom of the pack.
§ 02
What it's researched for
- weight loss
- type 2 diabetes
§ 03
Where to source it
top 3 by compositeSee all 2 vendors →
public-data
vendor · shut down
Amino Asylum
Permanently shut down June 2025 following an FDA raid. Do not order.
0/100
0d ship · last test 2026-03-28T00:00:00.000ZRead audit →
§ 04
Sources
read next
Other peptides
the roundup · monthly
Receipts in your inbox. Once a month.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.
14,200 subscribers· 0 sponsored items· 11 issues since launch